How the Type of Antiplatelet Agents Can Impact Patient Outcomes

Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses how the type of antiplatelet agent chosen can impact patient outcomes.

Christopher Betz, PharmD, BCPS, FKSHP, FASHP, professor in the department of clinical and administrative sciences at Sullivan University College of Pharmacy, discusses how the type of antiplatelet agent chosen can impact patient outcomes.

This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.

Related Content:

ConferenceRetail
Addressing Logistical Challenges of CAR T Therapy Administration in Inpatient, Outpatient Settings
Thrombocytopenia Syndrome Rates Following AstraZeneca COVID-19 Vaccine Dose Comparable to Unvaccinated Population
Anifrolumab Approved for Moderate to Severe Systemic Lupus Erythematosus